公开(公告)号：WO2023076991A1

公开(公告)日：2023-05-04

申请号：PCT/US2022/078771

申请日：2022-10-27

申请人： VERASTEM, INC.

发明人： PACHTER, Jonathan A. ,  CHOWDHURY, Sanjib ,  COMA, Silvia

IPC分类号： A61K31/352 ,  A61P35/00

摘要： Combinations of compounds as described herein, a BRAF V600 inhibitor, a pan-RAF inhibitor, a CRAF inhibitor, or a RAF inhibitor, and a dual RAF/MEK inhibitor, can be used, for example, in methods of treating abnormal cell growh/cancers in a subject in need thereof.

公开(公告)号：WO2023009572A1

公开(公告)日：2023-02-02

申请号：PCT/US2022/038434

申请日：2022-07-27

申请人： VERASTEM, INC. ,  FRANCIS CRICK INSTITUTE

发明人： COMA, Silvia ,  PACHTER, Jonathan A. ,  STUGLIK, Brian M. ,  DOWNWARD, Julian ,  MOLINA ARCAS, Miriam

IPC分类号： A61K31/33 ,  A61K31/18 ,  A61K31/4375 ,  A61K31/4433 ,  A61K31/00

摘要： The present disclosure relates to methods, compositions, and oral dosage forms of a dual RAF/MEK inhibitor, in combination with an anti-PD-1 antibody or an anti-PD-L1 antibody, and a KRAS G12C inhibitor, and optionally a FAK inhibitor, for treating abnormal cell growth (e.g., cancer).

公开(公告)号：WO2021154929A1

公开(公告)日：2021-08-05

申请号：PCT/US2021/015401

申请日：2021-01-28

申请人： VERASTEM, INC.

发明人： PACHTER, Jonathan A. ,  COMA, Silvia

IPC分类号： A61K31/519 ,  A61K31/5383 ,  A61P35/00 ,  A61P35/02 ,  C07D401/14 ,  C07D403/14

摘要： The present invention relates to methods, compositions, and oral dosage forms of a KRAS G12C inhibitor in combination with a FAK inhibitor and/or a MEK. inhibitor or a dual RAF/MEK inhibitor, for treating abnormal cell growth (e.g., cancer).

公开(公告)号：WO2016109426A1

公开(公告)日：2016-07-07

申请号：PCT/US2015/067671

申请日：2015-12-28

申请人： VERASTEM, INC.

发明人： PADVAL, Mahesh

IPC分类号： A61K31/5377

CPC分类号： A61K31/5377 ,  A61K45/06

摘要： The present invention relates to a method of treating a human subject having cancer, the method comprising administering to the subject a course of treatment comprising three (e.g., three, five) administrations of a compound of Formula (I) over a seven day period, wherein the compound is administered on days 1, 3, and 5 (e.g., 1, 3, and 5; 1, 2, 3, 4, and 5) of the seven day period, thereby treating the subject.

摘要翻译： 本发明涉及一种治疗患有癌症的人类受试者的方法，所述方法包括在七天的时间内向受试者施用包含式（I）化合物的三次（例如三次，五次）给药的治疗过程， 其中所述化合物在七天的第1,3和5天（例如，1,3和5; 1,2,3,4和5）施用，从而治疗受试者。

公开(公告)号：WO2015120289A1

公开(公告)日：2015-08-13

申请号：PCT/US2015/014843

申请日：2015-02-06

申请人： VERASTEM, INC.

发明人： XU, Qunli ,  PACHTER, Jonathan, A. ,  TAM, Winnie

IPC分类号： A61K39/00

CPC分类号： A61K31/506 ,  A61K9/0053 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4523 ,  A61K31/519 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer).

摘要翻译： 本发明特别涉及用于治疗异常细胞生长（例如癌症）的FAK抑制剂和MEK抑制剂的组合，方法，组合物和口服剂型。

公开(公告)号：WO2013134649A1

公开(公告)日：2013-09-12

申请号：PCT/US2013/029895

申请日：2013-03-08

申请人： VERASTEM, INC. ,  DERR, Alan, G. ,  WEAVER, David, T. ,  SHAPIRO, Irina ,  PATERSON, Daniel, W. ,  PACHTER, Jonathan, A.

发明人： DERR, Alan, G. ,  WEAVER, David, T. ,  SHAPIRO, Irina ,  PATERSON, Daniel, W. ,  PACHTER, Jonathan, A.

IPC分类号： C12Q1/68 ,  A61K39/395 ,  G01N33/53

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N33/57484 ,  G01N2800/52

摘要： Novel methods of classifying subjects as candidates for treatment with a cancer associated mesenchymal cell, tumor initiating cancer cell, or cancer stem cell inhibitor treatment and subsequent administration of the cancer associated mesenchymal cell, tumor initiating cancer cell, or cancer stem cell inhibitor are disclosed within.

摘要翻译： 将受试者分类为癌症相关间充质细胞，肿瘤起始癌细胞或癌干细胞抑制剂治疗和随后给予癌症相关间充质细胞，肿瘤起始癌细胞或癌症干细胞抑制剂的候选物的新方法公开在 。

公开(公告)号：WO2023081676A1

公开(公告)日：2023-05-11

申请号：PCT/US2022/079109

申请日：2022-11-02

申请人： VERASTEM, INC.

发明人： STUGLIK, Brian M. ,  KOUSTENIS, Andrew ,  PACHTER, Jonathan A. ,  COMA, Silvia

IPC分类号： A61K31/506 ,  A61K45/06 ,  A61P35/00

摘要： The present disclosure provides, in part, methods of reducing the severity of or preventing toxicity or an adverse event associated with administration of a dual RAF/MEK inhibitor in a subject, comprising administering to the subject an effective amount of the dual RAF/MEK inhibitor, an effective amount of an antibiotic agent, and optionally an effective amount of a corticosteroid.

公开(公告)号：WO2020072445A1

公开(公告)日：2020-04-09

申请号：PCT/US2019/053993

申请日：2019-10-01

申请人： VERASTEM, INC.

发明人： PACHTER, Jonathan A. ,  LELAND, Shawn

IPC分类号： A61K31/519 ,  A61K31/55 ,  A61P35/00

摘要： Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3 -kinase inhibitor, or a pharmaceutically acceptable form thereof, in combination with a CD47 inhibitor, or a pharmaceutically acceptable form thereof in the presence or absence of an opsonizing antibody. Also provided herein are methods of treatment comprising administration of the compositions, and uses of the compositions, e.g ., for treatment of cancer.

公开(公告)号：WO2013134658A1

公开(公告)日：2013-09-12

申请号：PCT/US2013/029909

申请日：2013-03-08

申请人： VERASTEM, INC.

发明人： WEAVER, David, T. ,  SHAPIRO, Irina ,  PATERSON, Daniel, W. ,  DERR, Alan, G. ,  PACHTER, Jonathan, A.

IPC分类号： C12Q1/68 ,  G01N33/48 ,  G01N33/53

CPC分类号： C12Q1/6886 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/574

摘要： Novel methods of classifying subjects as candidates for treatment with agent that inhibits or kills cancer associated mesenchymal cells, tumor initiating cancer cells, or cancer stem cells treatment and subsequent administration of the agent that inhibits or kills cancer associated mesenchymal cells, tumor initiating cancer cells, or cancer stem cells are disclosed within.

摘要翻译： 将受试者分类为用于抑制或杀死癌症相关的间充质细胞，肿瘤起始癌细胞或癌干细胞治疗和随后施用抑制或杀死癌症相关间充质细胞，肿瘤起始癌细胞的试剂的治疗候选物的新方法， 或癌干细胞。

公开(公告)号：WO2013085998A1

公开(公告)日：2013-06-13

申请号：PCT/US2012/067952

申请日：2012-12-05

申请人： VERASTEM, INC.

发明人： MA, Wendi ,  ELLIOTT, Peter ,  PADVAL, Mahesh

IPC分类号： A61K31/34 ,  A61K31/35

CPC分类号： A61K31/35 ,  A61K9/0019 ,  A61K9/08 ,  A61K45/06 ,  A61K47/10 ,  A61K47/14 ,  Y02A50/473 ,  Y02A50/481

摘要： Aqueous compositions comprising salinomycin, or a pharmaceutically acceptable salt thereof, miscible organic solvents, and solubilizers and/or emulsifying agents are disclosed. The formulations disclosed herein are useful in the treatment of cancer, especially cancers associated with cancer stem cells or cancerous mesenchymal cells. The method of treating a subject may further compriseidentifying a subject having a disorder suitable for treatment with the aqueous compositions described, comprising detecting one or more biomarkers predictive of the prevalence of a cancer having or enriched for cancer stem cells (CSCs).

摘要翻译： 公开了包含盐霉素或其药学上可接受的盐，可混溶的有机溶剂和增溶剂和/或乳化剂的水性组合物。 本文公开的制剂可用于治疗癌症，特别是与癌症干细胞或癌性间充质细胞相关的癌症。 治疗受试者的方法可进一步包括鉴定具有适合于所述含水组合物治疗的病症的受试者，其包括检测一种或多种预测癌症干细胞（CSCs）具有或富集癌症的癌症流行的生物标志物。